Analytical Data
-
基因名
Biglycan
- Application
-
别名
Bone/cartilage proteoglycan I (PG-S1)
-
种属
Mouse
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P28653
-
表达区间
38-369aa
-
分子量
43.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Biglycan is a small leucine-rich proteoglycan that plays a crucial role in the regulation of collagen fibril formation and the maintenance of extracellular matrix integrity. As a member of the small leucine-rich proteoglycan family, it is primarily found in connective tissues and has been implicated in various biological processes, including wound healing, inflammation, and tumor progression. Research on recombinant biglycan protein has gained significance due to its potential therapeutic applications in regenerative medicine and tissue engineering. By studying recombinant biglycan, scientists aim to elucidate its structural properties and functional roles in the extracellular matrix, which may pave the way for developing novel biomaterials that enhance tissue regeneration. Additionally, understanding the molecular mechanisms by which biglycan interacts with other extracellular matrix components can provide insights into the pathophysiology of various diseases, including osteoarthritis and cancer. As such, the development of recombinant biglycan not only offers opportunities for advanced biomaterial design but also opens up new avenues for targeted therapies that exploit its unique properties in modulating cellular behavior and tissue repair.
